SCHEMBL24876293

SCHEMBL24876293

CC1CCN(C(=O)/C=C/CF)[C@H](CC#N)C1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KRAS P01116 1/20 0.33
DPP4 P27487 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24876389 1.00 KRAS (0.33) KRASDPP4
SCHEMBL25445663 0.88
SCHEMBL24876304 0.85 KRAS (0.35) KRAS
SCHEMBL24876392 0.85 KRAS (0.35) KRAS
SCHEMBL25673246 0.85 DPP4 (0.32) KRASDPP4
SCHEMBL25066395 0.84 KRAS (0.32) KRASDPP4
SCHEMBL25066412 0.84 KRAS (0.32) KRASDPP4
SCHEMBL24543364 0.78 KRAS (0.38) KRASDPP4
SCHEMBL25504812 0.78 CHRM2 (0.34)
SCHEMBL30064865 0.75 CA1 (0.33) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091746-A1 COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR INCYTE CORPORATION (US) 2023-05-25 WO disclosed
WO-2023283213-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORPORATION (US) 2023-01-12 WO disclosed